Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Paul M. Barr
Research Funding - Gilead Sciences
Gene Brian Saylors
No relevant relationships to disclose
Stephen Edward Forbes Spurgeon
Research Funding - Gilead Sciences
Bruce D. Cheson
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Daniel Reif Greenwald
No relevant relationships to disclose
Susan Mary O'Brien
Research Funding - Gilead Sciences
Andre K. D. Liem
No relevant relationships to disclose
Rosemary McIntyre
No relevant relationships to disclose
Esteban Abella-Dominicis
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Michael J. Hawkins
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Anita Reddy
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Julie Di Paolo
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Meihua Wu
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Flordeliza Melchor-Khan
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Feng Jin
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Jonathan W. Friedberg
No relevant relationships to disclose